Facial resurfacing for nonmelanoma skin cancer prophylaxis

Archives of Dermatology

Volumn 142, Issue 8, 2006, Pages 976-982

  Hantash, Basil M ^a,b   Stewart, Daniel B ^a,b   Cooper, Zachary A ^a,b   Rehmus, Wingfield E ^b   Koch, R James ^a,c   Swetter, Susan M ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c California Face and Laser Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; TRICHLOROACETIC ACID;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CARBON DIOXIDE LASER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FACE SURGERY; FEMALE; HOSPITAL DEPARTMENT; HUMAN; LASER SURGERY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; PURPURA; RANDOMIZED CONTROLLED TRIAL; REJUVENATION; SCAR FORMATION; SIDE EFFECT; SKIN CANCER; SKIN PIGMENTATION; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CARBON DIOXIDE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FACE; FEMALE; FLUOROURACIL; HUMANS; KERATOLYTIC AGENTS; KERATOSIS; LASER THERAPY, LOW-LEVEL; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SCALP; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TREATMENT OUTCOME; TRICHLOROACETIC ACID;

EID: 33747626714     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.8.976     Document Type: Article

References (34)

1. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797.
2. Dodson JM, DeSpain J, Heweet JE, Clark DP. Maligant potential of actinic keratoses and the controversy over treatment. Arch Dermatol. 1991;127:1029-1031.
3. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol. 1991;127:1031-1033.
4. Czarnecki C, Czarnecki D. Patients who have multiple skin cancers develop new skin cancers at a constant rate [letter]. Arch Dermatol. 2002;138:125.
5. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol. 2000;136:1524-1530.
6. Friedman GD, Tekawa IS. Association of basal cell skin cancers with other cancers. Cancer Causes Control. 2000;11:891-897.
7. Feldman SR, Fleischer AB Jr, Williford PM, Jorizzo JL. Destructive procedures are the standard of care for the treatment of actinic keratoses. J Am Acad Dermatol. 1999;40:43-47.
8. Lober BA, Fenske NA. Optimum treatment strategies for actinic keratosis (intraepidermal squamous cell carcinoma). Am J Clin Dermatol. 2004;5:395-401.
9. Drake LA, Ceilley RI, Cornelison RL, et al; Committee on Guidelines of Care. Guidelines of care for actinic keratoses. J Am Acad Dermatol. 1995;32:95-98.
10. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol. 2004;3:401-407.
11. Korman N, Moy R, Ling M, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol. 2005;141:467-473.
12. David LM, Lask CP, Glassberg E, Jacoby R, Abergel RP. Laser ablation for cosmetic and medical treatment of facial actinic damage. Cutis. 1989;43:583-587.
13. Trimas SJ, Ellis DA, Metz RD. The carbon dioxide laser: an alternative for the treatment of actinically damaged skin. Dermatol Surg. 1997;23:885-889.
14. Massey RA, Eliezri YD. A case report of laser resurfacing as a skin cancer prophylaxis. Dermatol Surg. 1999;25:513-516.
15. Iyer S, Friedli A, Bowes L, Kricorian G, Fitzpatrick RE. Full face laser resurfacing: therapy and prophylaxis for actinic keratoses and non-melanoma skin cancer. Lasers Surg Med. 2004;34:114-119.
16. Witheiler DD, Lawrence N, Cox SE, Cruz C, Cockerell CJ, Freemen RG. Longterm efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Dermatol Surg. 1997;23:191-196.
17. Cooley JE, Casey DL, Kauffman CL. Manual resurfacing and trichloroacetic acid for the treatment of patients with widespread actinic damage: clinical and histologic observations. Dermatol Surg. 1997;23:373-379.
18. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD Jr. A comparison of the efficacy and safety of Jessner's solution and 35% trichloroacetic acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol. 1995;131:176-181.
19. Brodland DG, Roenigk RK. Trichloroacetic acid chemexfoliation (chemical peel) for extensive premalignant actinic damage of the face and scalp. Mayo Clin Proc. 1988;63:887-896.
20. Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of nonmelanoma skin cancer and actinic keratosis. Pharmacoeconomics. 2004;22:83-94.
21. Frankel DH, Hanusa BH, Zitella JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin: implications and recommendations for follow-up. J Am Acad Dermatol. 1992;26:720-726.
22. Marghoob A, Kopf AW, Bart RS, et al. Risk of another basal cell carcinoma developing after treatment of a basal cell carcinoma. J Am Acad Dermatol. 1993;28:22-28.
23. Chen GJ, Feldman SR, Williford PM, et al. Clinical diagnosis of actinic keratosis identifies an elderly population at high risk of developing skin cancer. Dermatol Surg. 2005;31:43-47.
24. Housman TS, Feldman SR, Williford PM, et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003;48:425-429.
25. Stockfleth E, Meyer T, Benninghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol. 2001;144:1050-1053.
26. Szeimies RM, Gerritsen MJ, Gupta G, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004;51:547-555.
27. Lebwohl M, Dinehart S, Whiting D, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-721.
28. Coleman WP III, Yarborough JM, Mandy SH. Dermabrasion for prophylaxis and treatment of actinic keratoses. Dermatol Surg. 1996;22:17-21.
29. Fulton JE, Rahimi AD, Helton P, et al. Disappointing results following resufracing of facial skin with CO2 lasers for prophylaxis of keratoses and cancers. Dermatol Surg. 1999;25:729-732.
30. Rubin MG. A peeler's thoughts on skin improvement with chemical peels and laser resurfacing. Clin Plast Surg. 1997;24:407-409.
31. Porter JP, Alford EL. Chemical peel. In: Frederickson JM, Harker LA, Krause CJ, et al, eds. Otolaryngology: Head and Neck Surgery. Baltimore, Md: Mosby-Year Book; 1998:640-647.
32. Fulton JE, Porumb S. Chemical peels: their place within the range of resurfacing techniques. Am J Clin Dermatol. 2004;5:179-187.
33. Tse Y, Ostad A, Lee HS, et al. A clinical and histologic evaluation of two medium-depth peels: glycolic acid versus Jessner's trichloroacetic acid. Dermatol Surg. 1996;22:781-786.
34. Humphreys TR, Werth V, Dzubow L, Kligman A. Treatment of photodamaged skin with trichloroacetic acid and topical tretinoin. J Am Acad Dermatol. 1996;34:638-644.